Gmax Biopharm LLC.

Gmax Biopharm LLC is a biopharmaceutical company that focuses on developing innovative therapeutic monoclonal antibodies to address various chronic diseases, including diabetes and obesity. Founded in 2010 and headquartered in Hangzhou, China, Gmax Biopharm LLC specializes in advanced biopharmaceuticals. The company has undergone strategic pivots to enhance its product offerings, primarily focusing on therapeutic monoclonal antibodies. Gmax has successfully raised funding through 2 deals, with the latest funding round being a Series C in March 2021, where they raised USD 78.

00 mn led by China Merchants Capital, alongside other investors such as Borui Capital and Tigermed. The founder's background is not specified, but the company has steadily progressed since its inception. Gmax Biopharm LLC specializes in the development of advanced biopharmaceutical products, focusing primarily on therapeutic monoclonal antibodies. Their main offerings include the GPCR Monoclonal Antibody Platform, targeting G protein-coupled receptors, and the M-Body Platform, designed to enhance the efficacy of antibody-based therapies.

The US FDA has approved their product GMA131 for clinical studies aimed at treating Diabetic Kidney Disease (DKD). Additionally, GMA106, a second-generation monoclonal antibody for obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic steatohepatitis (NASH), has progressed to the first human dosing stage. Gmax Biopharm’s products cater to healthcare providers, research institutions, and patients primarily in North America and select European markets. Gmax Biopharm generates revenue through strategic partnerships and clinical trials associated with their biopharmaceutical products.

The company's operational model relies on collaborations with healthcare institutions and research organizations, allowing access to key products like GMA131 and GMA106. Revenue is derived from licensing agreements and fees linked to clinical study collaborations, which support their financial foundation within the biopharmaceutical sector. Gmax Biopharm LLC plans to leverage the USD 78. 00 mn raised in their Series C funding to support the development of upcoming products and expand their market presence.

The company aims to introduce new products targeting chronic diseases and is actively exploring entry into additional European markets by late 2023. The funding will facilitate clinical trials and enhance their product pipeline, reinforcing Gmax's commitment to developing innovative therapies for obesity and diabetes.